Man Group’s Kalaris Therapeutics KLRS Stock Holding History

Man Group’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,702	Closed	-$264K	–	2460
2022 Q1	$264K	Buy	+1,702	New	+$340K	﹤0.01%	1815

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Man Group's KLRS Position: Q2 2022 in Review

Man Group sold out of Kalaris Therapeutics (KLRS) in Q2 2022, closing a stake of 1,702 shares — an estimated $264K sold.

Man Group first reported a position in KLRS in Q1 2022 and held it in 1 quarter. The position peaked at $264K in Q1 2022. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2022.

Man Group reported no remaining Kalaris Therapeutics position as of Q2 2022 after selling out during the quarter.
Man Group sold 1,702 Kalaris Therapeutics shares in Q2 2022, an estimated $264K.
Man Group first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 1 quarter.
Man Group's Kalaris Therapeutics position peaked at $264K in Q1 2022.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.